Use of azithromycin for the prevention of bronchopulmonary dysplasia in preterm infants: a randomized, double‐blind, placebo controlled trial

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Pediatric Pulmonology

• Publication date

  2011-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ppul.21352PMID 20963840
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Role of Ureaplasma Species in Neonatal Chronic Lung Disease: Epidemiologic and Experimental Evidence

  2009cited by this paper
• Chronic lung disease after premature birth.

  2008cited by this paper
• Long-Term Pulmonary Outcome in the Preterm Infant

  2008cited by this paper
• Azithromycin Suppresses Activation of Nuclear Factor-kappa B and Synthesis of Pro-inflammatory Cytokines in Tracheal Aspirate Cells From Premature Infants

  2007cited by this paper
• Azithromycin in the extremely low birth weight infant for the prevention of Bronchopulmonary Dysplasia: a pilot study

  2007cited by this paper
• Chronic lung disease after premature birth.

  2007cited by this paper
• Pulmonary outcomes in bronchopulmonary dysplasia.

  2006cited by this paper
• Nuclear Factor κB Activation in Pulmonary Leukocytes from Infants with Hyaline Membrane Disease: Associations with Chorioamnionitis and Ureaplasma urealyticum Colonization

  2005cited by this paper
• Critical Appraisal of the Role of Ureaplasma in the Development of Bronchopulmonary Dysplasia With Metaanalytic Techniques

  2005cited by this paper
• Mycoplasmas and Ureaplasmas as Neonatal Pathogens

  2005cited by this paper
• Validation of the National Institutes of Health Consensus Definition of Bronchopulmonary Dysplasia

  2005cited by this paper
• Experimental intrauterine Ureaplasma infection in sheep.

  2005cited by this paper
• Long-term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients.

  2005cited by this paper
• The effects of macrolides on inflammatory cells.

  2004cited by this paper
• Pulmonary Ureaplasma urealyticum Is Associated with the Development of Acute Lung Inflammation and Chronic Lung Disease in Preterm Infants

  2004cited by this paper
• Assessment of Antibiotic Susceptibility of Ureaplasma urealyticum from Prostitutes and Outpatient Clinic Patients Using the E-Test and Agar Dilution Method

  2003cited by this paper
• Improved lung function and body mass index associated with long-term use of Macrolide antibiotics.

  2003cited by this paper
• Bronchopulmonary dysplasia: changes in pathogenesis, epidemiology and definition.

  2003cited by this paper
• Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects.

  2002cited by this paper
• Ureaplasma urealyticum Induces Apoptosis in Human Lung Epithelial Cells and Macrophages

  2002cited by this paper
• Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial

  2002cited by this paper
• Antenatal infection/inflammation and postnatal lung maturation and injury

  2001cited by this paper
• Infectious Diseases of the Fetus and Newborn Infant

  2001influential reference
• Anti‐inflammatory effects of macrolides in lung disease *

  2001cited by this paper
• Bronchoalveolar inflammation following airway infection in preterm infants with chronic lung disease

  2001cited by this paper
• Anti-inflammatory activity of macrolide antibiotics.

  2000cited by this paper
• Comparison of Tissue Factor Pathway in Human Umbilical Vein and Adult Saphenous Vein Endothelial Cells: Implications for Newborn Hemostasis and for Laboratory Models of Endothelial Cell Function

  1999cited by this paper
• The New BPD: An Arrest of Lung Development

  1999cited by this paper
• The anti-inflammatory effects of macrolides

  1999cited by this paper
• Impact of erythromycin on respiratory colonization of Ureaplasma urealyticum and the development of chronic lung disease in extremely low birth weight infants.

  1998cited by this paper
• Randomised trial of erythromycin on the development of chronic lung disease in preterm infants

  1998cited by this paper
• Ureaplasma urealyticum respiratory tract colonization is associated with an increase in interleukin 1-beta and tumor necrosis factor alpha relative to interleukin 6 in tracheal aspirates of preterm infants.

  1998cited by this paper
• Susceptibilities of Neonatal Respiratory Isolates of Ureaplasma urealyticum to Antimicrobial Agents

  1998influential reference
• Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops.

  1996cited by this paper
• Neonatal Ureaplasma urealyticum colonization and chronic lung disease

  1994cited by this paper
• Serum concentrations of erythromycin after intravenous infusion in preterm neonates treated for Ureaplasma urealyticum infection.

  1994cited by this paper
• Frequency and significance of isolation of Ureaplasma urealyticum and Mycoplasma hominis from cerebrospinal fluid and tracheal aspirate specimens from low birth weight infants.

  1994cited by this paper
• Late pulmonary sequelae of bronchopulmonary dysplasia.

  1990cited by this paper

• Macrolides for the prevention of bronchopulmonary dysplasia in preterm neonates.

  2026cites this paper
• Nebulized Azithromycin as an Adjuvant Preventive Therapy for Bronchopulmonary Dysplasia in Preterm Infants: A Randomized Clinical Trial

  2026cites this paper
• Azithromycin for eradication of Ureaplasma and prevention of bronchopulmonary dysplasia in preterm infants: a meta-analysis

  2025cites this paper
• The Effect of Chronic Azithromycin Use in Winter on Health Care Utilization for Children With Bronchopulmonary Dysplasia: A Double Blind Randomized Controlled Study (RCT)

  2025cites this paper
• Azithromycin for Prevention of Bronchopulmonary Dysplasia and Other Neonatal Adverse Outcomes in Preterm Infants: An Updated Systematic Review and Meta-Analysis

  2025cites this paper
• Ureaplasma colonization increases the risk of moderate-severe bronchopulmonary dysplasia despite postnatal treatment in newborns: a retrospective study based on the latest diagnostic criteria for bronchopulmonary dysplasia.

  2025cites this paper
• Current and Emerging Therapies for Prevention and Treatment of Bronchopulmonary Dysplasia in Preterm Infants

  2025cites this paper
• [Advances in clinical pharmacotherapy for neonatal Ureaplasma urealyticum infection].

  2025cites this paper
• Prevalence, Prevention and Management of Bronchopulmonary Dysplasia

  2024influential citation
• Practical recommendations for neonatologists and pediatricians “Congenital ureaplasma, mycoplasma and chlamidia infections” (Draft of clinical recommendations for discussion by specialists)

  2024cites this paper
• EBNEO Commentary: Azithromycin therapy for prevention of chronic lung disease

  2024cites this paper
• Clinical Characteristics and Current Treatment Modality of Preterm Infants with Ureaplasma spp. Infection

  2024cites this paper
• Improving early diagnosis of bronchopulmonary dysplasia

  2024cites this paper
• The prevention and management strategies for neonatal chronic lung disease

  2023cites this paper
• Association of Ureaplasma infection pattern and azithromycin treatment effect with bronchopulmonary dysplasia in Ureaplasma positive infants: a cohort study

  2023cites this paper
• Pharmacotherapy of BPD: Current status & future perspectives.

  2023cites this paper
• Placing Ureaplasma within the Context of Bronchopulmonary Dysplasia Endotypes and Phenotypes

  2023cites this paper
• Azithromycin for Eradication of Ureaplasma and Prevention of Bronchopulmonary Dysplasia in Preterm Neonates in the Neonatal Intensive Care Unit.

  2023cites this paper
• Next-generation sequencing-based detection of Ureaplasma in the gastric fluid of neonates with respiratory distress and chorioamnionitis

  2023cites this paper
• AZTEC—azithromycin therapy for prevention of chronic lung disease of prematurity: a statistical analysis plan for clinical outcomes

  2022cites this paper
• Macrolides for the prevention of bronchopulmonary dysplasia in preterm neonates

  2022cites this paper
• Pharmacotherapy in Bronchopulmonary Dysplasia: What Is the Evidence?

  2022cites this paper
• The efficacy of hydrocortisone in preventing bronchopulmonary dysplasia: An integrative literature review

  2022cites this paper
• Eligibility Criteria and Representativeness of Randomized Clinical Trials That Include Extremely Premature Infants: A Systematic Review.

  2021cites this paper
• Ureasplasma and Its Role in Adverse Perinatal Outcomes: A Review.

  2021cites this paper
• The azithromycin to prevent wheezing following severe RSV bronchiolitis-II clinical trial: Rationale, study design, methods, and characteristics of study population

  2021cites this paper
• Validation of the loop-mediated isothermal amplification method for rapid and sensitive detection of Ureaplasma species in respiratory tracts of preterm infants

  2021influential citation
• Neonatologists’ Challenges During COVID-19 Pandemic

  2020cites this paper
• Neonatal Mycoplasma and Ureaplasma Infections.

  2020cites this paper
• Azithromycin for preventing bronchopulmonary dysplasia in preterm infants: A systematic review and meta‐analysis

  2020cites this paper
• Association between maternal cervicovaginal swab positivity for Ureaplasma spp. or other microorganisms and neonatal respiratory outcome and mortality

  2020cites this paper
• Use of Azithromycin for the Prevention of Lung Injury in Mechanically Ventilated Preterm Neonates: A Randomized Controlled Trial

  2020cites this paper
• Repurposing azithromycin for neuroprotection in neonates

  2019cites this paper
• Key paediatric messages from the 2018 European Respiratory Society International Congress

  2019cites this paper
• Neonatal azithromycin administration to prevent infant mortality: study protocol for a randomised controlled trial

  2019cites this paper
• CTGF: A potential therapeutic target for Bronchopulmonary dysplasia.

  2019cites this paper
• New antibiotic regimen for preterm premature rupture of membrane reduces the incidence of bronchopulmonary dysplasia

  2019cites this paper
• Pharmacotherapy for the Prevention of Bronchopulmonary Dysplasia: Can Anything Compete with Caffeine and Corticosteroids?

  2019cites this paper
• [Research progress in drug therapy for bronchopulmonary dysplasia in preterm infants].

  2018influential citation
• Neonatal Pneumonia

  2018cites this paper
• Optimum Detection of Ureaplasma in Premature Infants

  2018cites this paper
• Safety of azithromycin in infants under six months of age in Niger: A community randomized trial

  2018cites this paper
• Diagnostic value of chest CT combined with x-ray for premature infants with bronchopulmonary dysplasia

  2018cites this paper
• The Effect of Macrolide Therapy on Bronchopulmonary Dysplasia in Ureaplasma-Positive Very Low Birth Weight Infants

  2018cites this paper
• 198 – Ureaplasma urealyticum

  2018cites this paper
• Recent Advances in Bronchopulmonary Dysplasia: Pathophysiology, Prevention, and Treatment

  2018cites this paper
• The Future of Bronchopulmonary Dysplasia: Emerging Pathophysiological Concepts and Potential New Avenues of Treatment

  2017cites this paper
• Bronchopulmonary Dysplasia and Ureaplasma: What Do We Know So Far?

  2017cites this paper
• Airway Microbial Community Turnover Differs by BPD Severity in Ventilated Preterm Infants

  2017cites this paper
• Ureaplasma-associated prenatal, perinatal, and neonatal morbidities

  2017cites this paper
• Advances in emerging treatment options to prevent bronchopulmonary dysplasia

  2017cites this paper
• The Microbiome of the Lower Respiratory Tract in Premature Infants with and without Severe Bronchopulmonary Dysplasia

  2016cites this paper
• Anti-inflammatory Agents for the Prevention of Bronchopulmonary Dysplasia

  2016cites this paper
• Perinatal pharmacokinetics of azithromycin for cesarean prophylaxis.

  2015cites this paper
• Prevention of bacterial infections in the newborn by pre-delivery administration of azithromycin: Study protocol of a randomized efficacy trial

  2015cites this paper
• Role of Ureaplasma Respiratory Tract Colonization in Bronchopulmonary Dysplasia Pathogenesis: Current Concepts and Update.

  2015cites this paper
• Use and safety of azithromycin in neonates: a systematic review

  2015influential citation
• HIF-1α Plays a Critical Role in the Gestational Sidestream Smoke-Induced Bronchopulmonary Dysplasia in Mice

  2015cites this paper
• Evidence-Based Pharmacologic Therapies for Prevention of Bronchopulmonary Dysplasia: Application of the Grading of Recommendations Assessment, Development, and Evaluation Methodology.

  2015cites this paper
• Ureaplasma: Current perspectives

  2015cites this paper
• Macrolides do not affect the incidence of moderate and severe bronchopulmonary dysplasia in symptomatic ureaplasma‐positive infants

  2015cites this paper
• Adverse events in people taking macrolide antibiotics versus placebo for any indication.

  2015cites this paper
• Neonatal CNS infection and inflammation caused by Ureaplasma species: rare or relevant?

  2015influential citation
• Management of bronchopulmonary dysplasia

  2014cites this paper
• Ureaplasma, bronchopulmonary dysplasia, and azithromycin in European neonatal intensive care units: a survey

  2014cites this paper
• A systematic review of randomized controlled trials for the prevention of bronchopulmonary dysplasia in infants

  2014cites this paper
• An optimal LC-MS/MS method for determination of azithromycin in white blood cells: application to pediatric samples.

  2014cites this paper
• Association Between Pulmonary Ureaplasma Colonization and Bronchopulmonary Dysplasia in Preterm Infants: Updated Systematic Review and Meta-analysis

  2014cites this paper
• Azithromycin and Other Macrolides for Prevention of Bronchopulmonary Dysplasia: A Systematic Review and Meta-Analysis

  2014cites this paper
• Pharmacokinetics, Microbial Response, and Pulmonary Outcomes of Multidose Intravenous Azithromycin in Preterm Infants at Risk for Ureaplasma Respiratory Colonization

  2014cites this paper
• The airway microbiome of intubated premature infants: characteristics and changes that predict the development of bronchopulmonary dysplasia

  2014cites this paper
• Bronchopulmonary dysplasia: clinical perspective.

  2014cites this paper
• Ureaplasma species: role in neonatal morbidities and outcomes

  2013cites this paper
• Azithromycin To Prevent Bronchopulmonary Dysplasia in Ureaplasma-Infected Preterm Infants: Pharmacokinetics, Safety, Microbial Response, and Clinical Outcomes with a 20-Milligram-per-Kilogram Single Intravenous Dose

  2013cites this paper
• Orphan drugs in bronchopulmonary dysplasia

  2013cites this paper
• Perinatal prevention of bronchopulmonary dysplasia

  2013cites this paper
• Azithromycin to Prevent Bronchopulmonary Dysplasia in Ureaplasma-infected Preterm

  2013cites this paper
• An update on pharmacologic approaches to bronchopulmonary dysplasia.

  2013cites this paper
• Role of Biofilm Formation in Ureaplasma Antibiotic Susceptibility and Development of Bronchopulmonary Dysplasia in Preterm Neonates

  2013cites this paper
• Ureaplasma and BPD.

  2013cites this paper
• Developmental innate immunoinsufficiency: Comparison of term neonatal neutrophil proteinases and complement component levels relative to adults

  2012cites this paper
• PREVENTIVE AND THERAPEUTIC APPROACHES FOR BRONCHOPULMONARY DYSPLASIA-AN UPDATE

  2012cites this paper
• The Ureaplasma Conundrum

  2012cites this paper
• Clarithromycin in Preventing Bronchopulmonary Dysplasia in Ureaplasma urealyticum–Positive Preterm Infants

  2012cites this paper
• Clarithromycin in Preventing Bronchopulmonary Dysplasia in Ureaplasma urealyticum–Positive Preterm Infants

  2012cites this paper
• Efficacy of azithromycin for prevention of bronchopulmonary dysplasia (BPD)

  2012cites this paper
• Appropriate antibiotic therapy improves Ureaplasma sepsis outcome in the neonatal mouse

  2012cites this paper
• Hepatic injury to the newborn liver due to drugs.

  2012cites this paper
• The association between respiratory tract Ureaplasma urealyticum colonization and severe retinopathy of prematurity in preterm infants ≤1250 g

  2012cites this paper
• A developmental approach to drug-induced liver injury in newborns and children.

  2012cites this paper
• Bronchopulmonary dysplasia.

  2012cites this paper
• Antenatal exposure to Ureaplasma species exacerbates bronchopulmonary dysplasia synergistically with subsequent prolonged mechanical ventilation in preterm infants

  2012cites this paper
• Azithromycin, Ureaplasma and chronic lung disease of prematurity: a case study for neonatal drug development

  2011cites this paper
• Clarithromycin in Preventing Bronchopulmonary Dysplasia in Ureaplasma urealyticum–Positive Preterm Infants

  2011cites this paper
• The Transition from Bronchopulmonary Dysplasia to Childhood Chronic Lung Disease

  2011cites this paper
• The management of neonatal pulmonary hypertension

  2011cites this paper
• Molecular Identification of Bacteria in Tracheal Aspirate Fluid from Mechanically Ventilated Preterm Infants

  2011cites this paper
• Etiology of Bronchopulmonary Dysplasia: Before Birth

  2011cites this paper
• Epigenetic influences in the development of bronchopulmonary dysplasia

  2011cites this paper
• Pathogenesis of Bronchopulmonary Dysplasia

  2009cites this paper